ELISA: 1: 40000approx. 1: 60000. WB: 1: 500approx. 1: 1000. IHC: 1: 50approx. 1: 200. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Dopaminergic signaling pathways, which are essential for multiple brain functions, are abnormal in several neurological disorders, such as schizophrenia, Parkinson's disease and drug abuse. DARPP-32 (for dopamine and adenosine 3',5'-monophosphate-regulated phosphoprotein of 32 kDa) is abundant in neurons that receive dopaminergic input. Activation of PKA and the consequent phosphorylation of DARPP-32 on threonine occurs in response to dopamine acting upon D1-like receptors. Dopamine interaction with D2-like receptors results in the inhibition of PKA activation, the activation of protein phosphatase 2B and the consequent dephosphorylation of DARPP-32. Neurotransmitters other than dopamine may also be able to stimulate the phosphorylation or dephosphorylation of DARPP-32. Phosphorylated DARPP-32 is a potent inhibitor of PP-1.Synonyms: DARPP-32, Dopamine- and cAMP-regulated neuronal phosphoprotein, FLJ20940, PPP1R1B, Protein phosphatase 1 regulatory subunit 1B